HIV-1 has infected 37.8 million persons in the world and 1.2 million are living with HIV-1 in the U.S. New York has the most AIDS cases at 172,370 (18% of the U.S. total) and the highest case rate at 32.7/10A5. South Africa, which has <2% of the world's population, is home to 30% of all the people living with HIV/AIDS in the world (5.3 million). HAART reduces plasma viral load below the limits of detection in most patients, increases CD4+ counts, and reduces the incidence of opportunistic infections. Pulmonary infectious complications are still recognized: bacterial pneumonia, tuberculosis, CMV and PCP. We hypothesize that bacterial pneumonia occurs in the HAART era, albeit at a lower incidence, and will enhance local HIV-1 replication and mutation.
AIM 1 will enroll 200 HIV-1+ patients each at New York and Cape Town, collect questionnaires, blood, sputum, PFT, and follow them prospectively for 4 annual visits.
AIM 2 will study 36 HIV-1+ patients with bacterial pneumonia and 72 HIV-1 + controls at each site with bronchoalveolar lavage (BAL) of involved/uninvolved lobes. HIV-1 will be quantitated in involved and uninvolved lobes and plasma with the expectation that inflammation with PMNs may drive macrophage HIV-1 transcription increasing HIV- 1 RNA viral load, RT-PCR in macrophages and increased envelope V3 loop mutations and drug resistance mutations in involved lobes. We will characterize the cells in lung and blood with surface markers using flow cytometry.
AIM 3 will evaluate macrophage-PMN interaction to determine the mechanisms of Reactive Oxidant Species damage that may cause mutations using in vitro experiments and BAL cells. We will evaluate Treg suppressive function in Cape Town to determine effects of HAART and HIV-1 on Tregs followed by changes caused by bacterial pneumonia in involved/uninvolved lobe compartments. This research will provide guidance on HAART therapy in HIV-1+ patients, particularly when the CD4+ level is preserved >250 cells/ml and whether HAART can prevent bacterial pneumonia, or alter its clinical features. We will also determine whether bacterial pneumonia predisposes to HAART failure, and if pneumonia in patients with CD4+ should be started on HAART because the focal lung inflammation increases HIV-1 replication and mutations. In this prospective study, we will also evaluate latent tuberculosis and other respiratory infections to determine their influence on the course of HIV-1 infection. We will use high-speed FACS cell sorting to separate macrophages, lymphocytes, and neitrophils for mechanistic studies. We will freeze and store at -70 degrees plasma, serum, PBMC (RNA, DNA, protein), BAL, from involved/uninvolved lung segments, and sputum for collaborative studies with other NHLBI grantees.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL090316-03
Application #
7644980
Study Section
Special Emphasis Panel (ZHL1-CSR-Z (S1))
Program Officer
Peavy, Hannah H
Project Start
2007-09-28
Project End
2012-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$800,502
Indirect Cost
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Segal, Leopoldo N; Clemente, Jose C; Wu, Benjamin G et al. (2017) Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax 72:13-22
Segal, Leopoldo N; Clemente, Jose C; Li, Yonghua et al. (2017) Anaerobic Bacterial Fermentation Products Increase Tuberculosis Risk in Antiretroviral-Drug-Treated HIV Patients. Cell Host Microbe 21:530-537.e4
Leader, Joseph K; Crothers, Kristina; Huang, Laurence et al. (2016) Risk Factors Associated With Quantitative Evidence of Lung Emphysema and Fibrosis in an HIV-Infected Cohort. J Acquir Immune Defic Syndr 71:420-7
Tsay, Jun-Chieh J; Li, Zhiguo; Yie, Ting-An et al. (2015) Molecular characterization of the peripheral airway field of cancerization in lung adenocarcinoma. PLoS One 10:e0118132
Drummond, M Bradley; Huang, Laurence; Diaz, Philip T et al. (2015) Factors associated with abnormal spirometry among HIV-infected individuals. AIDS 29:1691-700
Cho, Soo Jung; Echevarria, Ghislaine C; Kwon, Sophia et al. (2014) One airway: Biomarkers of protection from upper and lower airway injury after World Trade Center exposure. Respir Med 108:162-70
Nolan, Anna; Fajardo, Elaine; Huie, Maryann L et al. (2013) Increased production of IL-4 and IL-12p40 from bronchoalveolar lavage cells are biomarkers of Mycobacterium tuberculosis in the sputum. PLoS One 8:e59461
Crothers, Kristina; McGinnis, Kathleen; Kleerup, Eric et al. (2013) HIV infection is associated with reduced pulmonary diffusing capacity. J Acquir Immune Defic Syndr 64:271-8
Weiden, Michael D; Naveed, Bushra; Kwon, Sophia et al. (2013) Cardiovascular biomarkers predict susceptibility to lung injury in World Trade Center dust-exposed firefighters. Eur Respir J 41:1023-30
Nolan, A; Condos, R; Huie, M L et al. (2013) Elevated IP-10 and IL-6 from bronchoalveolar lavage cells are biomarkers of non-cavitary tuberculosis. Int J Tuberc Lung Dis 17:922-7

Showing the most recent 10 out of 23 publications